In vivo electrophysiological recordings of cardiac SNA reveals the critical importance of this sub-population of oxytocin neurons for mediating the increase in cardiac SNA and, in doing so, identifies the highly specific oxytocin receptor antagonist, retosiban, as a promising therapy for the first-line treatment of patients who suffer an acute MI. This evidence concerns the gene OXT and myocardial infarction.